Beckman Coulter Diagnostics launches fully automated urinalysis System to meet rising testing volumes. July 23, 2026 los angeles biotechnology network news los angeles biotech news comments off on Beckman Coulter Diagnostics launches fully automated urinalysis System to meet rising testing volumes. The DxU 1800 System features new urine chemistry analyzer and consumables with market-leading microscopy helping laboratories to meet rising diagnostic demand BREA, Calif., July 23, 2026 /PRNewswire/ - Beckman Coulter Diagnostics, a Danaher company and a global leader in clinical...

Beckman Coulter Diagnostics has launched the DxU 1800 System, a fully automated urinalysis solution for US laboratories. Unveiled at the Association for Diagnostics & Laboratory Medicine Annual Scientific Meeting, the system combines a new chemistry analyser with microscopy technology. The platform aims to address rising demand for urinalysis testing, which features in roughly one in three US emergency department visits. The DxU 1800c Chemistry analyser can process up to 300 samples per hour and stores up to 2,000,000 samples. When integrated with microscopy, the system reduces manual review rates to less than 3 per cent. Beckman Coulter Diagnostics is part of Danaher, a global science and technology company.

NanoSomiX and Beckman Coulter partner to develop blood tests for brain diseases. The collaboration aims to develop automated tests that use blood samples to detect signals of neurological conditions. NanoSomiX and Beckman Coulter Diagnostics have entered a collaboration to explore the development of next-generation immunoassays for neurodegenerative diseases. The partnership focuses on addressing challenges in detecting low-abundance, brain-specific biomarkers in blood. The companies are utilizing a platform from NanoSomiX that isolates extracellular vesicles (EVs) derived from specific brain cell populations, including neurons and glial cells. "EVs - particularly brain-derived EVs - offer a non-invasive way to access meaningful signals from the brain using a small volume of blood," says Dr Dennis Van Epps, vp, scientific affairs at NanoSomiX, in a release. "NanoSomiX has developed EV-based immunoassays that measure biomarkers from neuron- and other brain cell-derived EVs, supporting research into disease mechanisms, progression, and therapeutic response." The collaboration with Beckman Coulter Diagnostics is intended to help translate these EV-based immunoassays into automated and scalable solutions for use in both research and clinical laboratory settings. NanoSomiX has published research regarding its immunoassay platforms, which are designed to be compatible with high-throughput testing systems. According to the company, this compatibility positions the technology as a foundation for translational research and the development of scalable assays. The company currently works with academic and commercial partners on research involving EVs derived from neurons, astrocytes, and oligodendrocytes. These efforts are intended to advance biomarker discovery and validation across a range of neurological conditions and injuries.